Table 1.
Summary of the Studies with Sofosbuvir and Daclatasvir for COVID-19.
| Author | Inclusion criteria | Treatment vs. control arm | Age (years, IQR) | Time to clinical recovery | Recovered | ICU admission | Mortality |
|---|---|---|---|---|---|---|---|
| Eslami G et al.9 | Adults with positive SARS-CoV-2 PCR and/or CT chest with spo2<94%/RR>24/decreased level of consciousness N-62 Severe disease |
Sofosbuvir–daclatasvir (35) vs. ribavirin (27) for 14 days Both arms received lopinavir/ritonavir & hydroxychloroquine |
62 (47–69)v s. 60 (43–73) |
6 days vs.11 days (P-<0.01) | 94% vs.67% (P-0.01) | 17% vs.48% (P-0.01) | 5.7% vs.33% (P-0.01) RR (95%CI) 0.17 (0.04–0.73) vs. 5.8 (1.4–25) (P-0.02) |
| Abbaspour Kasgari H et al.10 | Adults with positive SARS-CoV-2 PCR and/or CT chest with spo2>94%/RR < 24/symptom onset ≤8 days prior to admission N-48 Moderate disease |
Sofosbuvir–daclatasvir and ribavirin (24) vs. hydroxychloroquine and lopinavir/ritonavir with or without ribavirin (24) | 45 (38–69)v s. 60 (47.5–68.5) |
6 days vs. 6 days | 100% vs. 88% (P-0.23) | 0 vs. 17% (P-0.10) | 0 vs. 13% (P-0.23) |
| Sadeghi A et al.8 | Adults with positive SARS-CoV-2 PCR with fever (≥37.8 °C) plus at least one of: respiratory rate >24/min, spo2 <94% or Pa02/Fi02 ratio <300 mghg N-66 Severe disease |
Sofosbuvir–daclatasvir for 14 days (33)+ lopinavir/ritonavir vs. lopinavir/ritonavir (33) | 58 vs. 62 | 6 days vs. 11 days (P-0.04) | Clinical improvement within 14 days 88% vs 67% (P = 0.076) |
9% vs. 21% (P-0.30) | 9% vs.15% (P-0.70) |
CT, computed tomography scan; ICU, Intensive care unit; IQR, interquartile range; PCR, polymerase chain reaction; RR, relative risk; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; vs., versus.